Anna Laqua

Kiel, SH, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Blinatumomab-driven T-cell activation in αβ and γδ T-cell subsets: insights from in vitro assays.

Blinatumomab-driven T-cell activation in αβ and γδ T-cell subsets: insights from in vitro assays.

Journal: Frontiers in immunology
Published: November 04, 2025

Complementary efficacy of CD127-directed immunotherapy with lusvertikimab and ABL-targeting tyrosine kinase inhibitors in preclinical ABL-class-fusion-positive B-ALL.

Complementary efficacy of CD127-directed immunotherapy with lusvertikimab and ABL-targeting tyrosine kinase inhibitors in preclinical ABL-class-fusion-positive B-ALL.

Journal: HemaSphere
Published: September 09, 2025

Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial.

Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial.

Journal: Leukemia
Published: May 28, 2025

Allogeneic Hematopoietic Stem Cell Transplantation From a CD36+ Donor in an Immunized Patient With Type I Hereditary CD36 Deficiency.

Allogeneic Hematopoietic Stem Cell Transplantation From a CD36+ Donor in an Immunized Patient With Type I Hereditary CD36 Deficiency.

Journal: Transplantation
Published: February 28, 2025

NGS-based IG/TR gene rearrangement profiling in acute lymphoblastic leukemia: age dependence of immunogenetic maturation.

NGS-based IG/TR gene rearrangement profiling in acute lymphoblastic leukemia: age dependence of immunogenetic maturation.

Journal: Blood
Published: October 08, 2024

Minimal residual disease assessment following CD19-targeted therapy in B-cell precursor acute lymphoblastic leukemia using standardized 12-color flow cytometry: A EuroFlow study.

Minimal residual disease assessment following CD19-targeted therapy in B-cell precursor acute lymphoblastic leukemia using standardized 12-color flow cytometry: A EuroFlow study.

Journal: HemaSphere
Published: September 25, 2024

The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis.

The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis.

Journal: Blood
Published: May 08, 2023

Minimal residual disease assessment in B-cell precursor acute lymphoblastic leukemia by semi-automated identification of normal hematopoietic cells: A EuroFlow study.

Minimal residual disease assessment in B-cell precursor acute lymphoblastic leukemia by semi-automated identification of normal hematopoietic cells: A EuroFlow study.

Journal: Cytometry. Part B, Clinical cytometry
Published: December 23, 2022

CD20 Expression as a Possible Novel Prognostic Marker in CLL: Application of EuroFlow Standardization Technique and Normalization Procedures in Flow Cytometric Expression Analysis.

CD20 Expression as a Possible Novel Prognostic Marker in CLL: Application of EuroFlow Standardization Technique and Normalization Procedures in Flow Cytometric Expression Analysis.

Journal: Cancers
Published: August 17, 2022

Preclinical Evidence for the Efficacy of CD79b Immunotherapy in B-cell Precursor Acute Lymphoblastic Leukemia.

Preclinical Evidence for the Efficacy of CD79b Immunotherapy in B-cell Precursor Acute Lymphoblastic Leukemia.

Journal: HemaSphere
Published: April 20, 2022

Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies - a EuroFlow study.

Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies - a EuroFlow study.

Journal: British journal of haematology
Published: September 24, 2021

Bispecific antibodies in acute lymphoblastic leukemia therapy.

Bispecific antibodies in acute lymphoblastic leukemia therapy.

Journal: Expert review of hematology
Published: October 01, 2020
Showing 1-12 of 12

Last Updated: 09/26/2026